Expanded Access to Veliparib

N/ANo Longer AvailableNCT03123211

AbbVie

Overview

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to veliparib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. EAP is also available for other indications where there is reasonable scientific basis for efficacy.

Expanded Access

Study Type

EXPANDED_ACCESS

Conditions

Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian Cancer Patients Requiring Veliparib Suspension Formulation

Interventions

VeliparibDRUG

Veliparib will be administered orally.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * The patient has relapsed/refractory disease and exhausted all standard treatments. * The patient has documented Breast Cancer (BRCA), BRCA associated RING domain (BARD), or Partner and Localizer of Breast Cancer (PALB) or other acceptable deoxyribonucleic acid (DNA) mutations. Exclusion Criteria: * The patient is eligible for a Poly Adenosine diphosphate ribose polymerase (PARP) inhibitor clinical trial. * The patient has previously received a PARP inhibitor for the same disease.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.